您好,欢迎来到试剂信息网! [登录] [免费注册]
试剂信息网
位置:首页 > 产品库 > 5,8,11-Eicosatriynoic Acid
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
5,8,11-Eicosatriynoic Acid
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
5,8,11-Eicosatriynoic Acid图片
CAS NO:13488-22-7
包装与价格:
包装价格(元)
1mg电议
5mg电议
10mg电议

产品介绍
nonselective inhibitor of lipoxygenases (12-LO)
Cas No.13488-22-7
别名5,8,11-十二烯酸,5,8,11-ETI
化学名5,8,11-eicosatriynoic acid
Canonical SMILESCCCCCCCCCCCCCCCCCCCC(=O)O
分子式C20H28O2
分子量300.4
溶解度≤20mg/ml in ethanol;20mg/ml in DMSO;20mg/ml in dimethyl formamide
储存条件Store at -20℃
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

5,8,11-Eicosatriynoic Acid is a selective inhibitor of lipoxygenases with ID50 values of 24 μM and 340 μM for n-8 lipoxygenase and fatty acid cycle-oxygenase , respectively[1][2].

Fatty acid cycle-oxygenase and n-8 lipoxygenase catalyze the initial reactions which lead to the formation of three major arachidonic acid metabolites in human platelets. In several tissues, these two enzymes act concomitantly on arachidonic acid [1].

5,8,11-Eicosatriynoic Acid (5,8,11-ET) is a selective inhibitor of lipoxygenases with ID50 values of 24 μM and 340 μM for n-8 lipoxygenase and fatty acid cycle-oxygenase, respectively. 5,8,11-Eicosatriynoic acid was useful for studies on physiological and pathophysiological roles of 12 L-hydroxy-5,8,10,14-eicosatetraenoic acid formation in various tissues [1]. In mouse mastocytoma cells, 5,8,11-Eicosatriynoic Acid inhibited A23187 and L-cysteine induced leukotriene C (LTC4) biosynthesis with ID50 value of 5 μM [2].

References:
[1].  Hammarstrm S. Selective inhibition of platelet n-8 lipoxygenase by 5,8,11-eicosatriynoic acid. Biochim Biophys Acta. 1977 Jun 22;487(3):517-9.
[2].  Orning L, Hammarstrm S. Inhibition of leukotriene C and leukotriene D biosynthesis. J Biol Chem. 1980 Sep 10;255(17):8023-6.